Oshima A, Higuchi T, Fujiwara Y, Iida M, Iwanami A, Kanba S, Motohashi N, Uchitomi Y, Yamada K, Yamawaki S
Showa University Fujigaoka Hospital, Kanagawa, Japan.
Psychiatry Clin Neurosci. 1999 Oct;53 Suppl:S67-72.
The answers to a questionnaire on the practical prescription in mood disorders from 298 Japanese psychiatrists was obtained. As the first-line treatment, a majority of respondents chose newer tricyclic agents (TCA) or non-TCA for moderate depression and older TCA for severe depression both with and without psychotic features. Combination therapy with antidepressants and anxiolytics was fairly popular in moderate depression, while antidepressant/neuroleptic combination was more common in severe psychotic depression. Sulpiride was the most favored drug for dysthymia. Although lithium was the most popular for bipolar mania, respondents were divided on the treatment of bipolar depression.
获得了298名日本精神科医生关于心境障碍实际处方的问卷调查答案。作为一线治疗，大多数受访者对于中度抑郁症选择新型三环类药物（TCA）或非TCA，对于重度抑郁症（无论有无精神病性特征）选择老式TCA。抗抑郁药与抗焦虑药的联合治疗在中度抑郁症中相当普遍，而抗抑郁药/抗精神病药联合治疗在重度精神病性抑郁症中更为常见。舒必利是治疗恶劣心境最受青睐的药物。虽然锂盐是治疗双相躁狂最常用的药物，但受访者在双相抑郁症的治疗上存在分歧。
